中文_japan medicine

> 主页 > 中文 >

中文

BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06/C/xinwenzixun/2026/0506/5463.html" title="BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应">BRAF抑制剂达拉非尼Tafinlar：肿瘤精准治疗临床应2026-05-06
蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06/C/xinwenzixun/2026/0506/5462.html" title="蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床">蛋白酶体抑制剂伊沙佐米Ninlaro：靶向机制与临床2026-05-06
Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06/C/xinwenzixun/2026/0506/5461.html" title="Darzalex获欧盟批准，开创高风险SMM早期治疗先河">Darzalex获欧盟批准，开创高风险SMM早期治疗先河2026-05-06
口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06/C/xinwenzixun/2026/0506/5460.html" title="口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势">口服靶向药伊沙佐米：多发性骨髓瘤治疗的优势2026-05-06
PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06/C/xinwenzixun/2026/0506/5459.html" title="PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适">PARP抑制剂奥拉帕利Olaparib：靶点机制与实体瘤适2026-05-06

Drug Catalogue

联系我们

QQ: 812578480

手机: 13206347272

电话: 13206347272

邮箱:

地址: Setting addresses in the background